Case report reveals KMT2A amplification impacting outcomes in mixed-phenotype acute leukemia.
The amplification of KMT2A, a gene involved in hematopoietic stem cell function, is extremely rare in acute leukemias, especially in mixed-phenotype acute leukemia. We present the case of a 62-year-old patient diagnosed with acute myeloid leukemia, myelodysplasia-related (AML-MR) with immunophenotypic features suggestive of B/myeloid mixed-phenotype acute leukemia (MPAL), with the presence of multiple KMT2A gene amplifications and a very aggressive and complicated clinical course ending in failure despite intensive treatment. KMT2A amplification in MPAL could be a risk factor suggesting adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Łączak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: